Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-14
2010-06-15
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S184000, C546S192000, C546S199000, C514S315000, C514S317000, C514S320000
Reexamination Certificate
active
07737163
ABSTRACT:
This invention relates to compounds of the formula (I):wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
REFERENCES:
patent: 5137893 (1992-08-01), Becker et al.
patent: 5196547 (1993-03-01), Becker et al.
patent: 5219850 (1993-06-01), Becker et al.
patent: 5223511 (1993-06-01), Turconi et al.
patent: 5260303 (1993-11-01), Becker et al.
patent: 5280028 (1994-01-01), Flynn et al.
patent: 5300512 (1994-04-01), Flynn et al.
patent: 5358954 (1994-10-01), Turconi et al.
patent: 5399562 (1995-03-01), Becker et al.
patent: 5434161 (1995-07-01), Becker et al.
patent: 5521193 (1996-05-01), Flynn et al.
patent: 5534521 (1996-07-01), Flynn et al.
patent: 5552408 (1996-09-01), Turconi et al.
patent: 5576318 (1996-11-01), Bietti et al.
patent: 5591749 (1997-01-01), Becker et al.
patent: 5604239 (1997-02-01), Becker et al.
patent: 5705498 (1998-01-01), Gaster et al.
patent: 5864039 (1999-01-01), Kawakita et al.
patent: 5922733 (1999-07-01), Forbes et al.
patent: 5955470 (1999-09-01), Gittos
patent: 5968965 (1999-10-01), Dinsmore et al.
patent: 6002009 (1999-12-01), Cereda et al.
patent: 6069152 (2000-05-01), Schaus et al.
patent: 6106864 (2000-08-01), Dolan et al.
patent: 6117882 (2000-09-01), Schaus et al.
patent: 6207697 (2001-03-01), Han et al.
patent: 6310059 (2001-10-01), Snutch
patent: 6420410 (2002-07-01), Sperl et al.
patent: 6492375 (2002-12-01), Snutch
patent: 6548548 (2003-04-01), Campbell et al.
patent: 6552042 (2003-04-01), Han et al.
patent: 6624162 (2003-09-01), Uchida et al.
patent: 6624184 (2003-09-01), Gu et al.
patent: 6713650 (2004-03-01), Ibrahim et al.
patent: 6919339 (2005-07-01), Campbell et al.
patent: 2002/0128232 (2002-09-01), Henderson et al.
patent: 2003/0207875 (2003-11-01), Gymer et al.
patent: 2004/0122043 (2004-06-01), Iguchi et al.
patent: 2004/0127514 (2004-07-01), Katsu et al.
patent: 2005/0148573 (2005-07-01), Katsu et al.
patent: 0105763 (1984-04-01), None
patent: 0274867 (1988-07-01), None
patent: 0377967 (1990-07-01), None
patent: 0504679 (1992-09-01), None
patent: 0623621 (1994-04-01), None
patent: 0655439 (1995-05-01), None
patent: 0908459 (1999-04-01), None
patent: 1217000 (2002-06-01), None
patent: 2694292 (1992-02-01), None
patent: 1258674 (1989-10-01), None
patent: 2643274 (1997-05-01), None
patent: 10203987 (1998-08-01), None
patent: 20016877 (2001-01-01), None
patent: WO9100858 (1991-01-01), None
patent: WO9111172 (1991-08-01), None
patent: WO9116045 (1991-10-01), None
patent: WO9205174 (1992-04-01), None
patent: WO9212149 (1992-07-01), None
patent: WO9215593 (1992-09-01), None
patent: WO9307147 (1993-04-01), None
patent: WO9308185 (1993-04-01), None
patent: WO9318027 (1993-09-01), None
patent: WO9400449 (1994-01-01), None
patent: WO9402518 (1994-02-01), None
patent: WO9407859 (1994-04-01), None
patent: WO9408998 (1994-04-01), None
patent: WO9410174 (1994-05-01), None
patent: WO9429298 (1994-12-01), None
patent: WO9605166 (1996-02-01), None
patent: WO9631475 (1996-10-01), None
patent: WO9717345 (1997-05-01), None
patent: WO9727852 (1997-08-01), None
patent: WO9738665 (1997-10-01), None
patent: WO9847898 (1998-10-01), None
patent: WO9855148 (1998-12-01), None
patent: WO9912903 (1999-03-01), None
patent: WO9917772 (1999-04-01), None
patent: WO9950247 (1999-10-01), None
patent: WO9950264 (1999-10-01), None
patent: WO9964055 (1999-12-01), None
patent: WO0026197 (2000-05-01), None
patent: WO0035298 (2000-06-01), None
patent: WO0105763 (2001-01-01), None
patent: WO0114331 (2001-03-01), None
patent: WO0146166 (2001-06-01), None
patent: WO0164631 (2001-09-01), None
patent: WO0230886 (2002-04-01), None
patent: WO0246141 (2002-06-01), None
patent: WO2004113300 (2004-12-01), None
patent: WO2005021539 (2005-03-01), None
Murcia, C. Marta. “Diseño y síntesis de nuevos antagonistas selectivos del receptor serotoninérgico 5-HT4” (Universidad Complutense de Madrid, 2001).
Roy et al., Circulation, vol. 94, No. 4, pp. 817-823, 1996.
U.S. Appl. No. 11/153,775, filed Jun. 14, 2005 (assigned to Pfizer Inc.).
U.S. Appl. No. 11/153,757, filed Jun. 14, 2005 (assigned to Pfizer Inc.).
U.S. Appl. No. 10/933,629, filed Sep. 2, 2004, published as US 2005/0148473 cited above (assigned to Pfizer Inc.).
Bockaert, J., et al., The 5-HT4receptor: a place in the sun,TipS, vol. 13, pp. 141-145, 1992.
Ford, A. P. D. W., et al., The 5-HT4Receptor,Medicinal Research Reviews, vol. 13, No. 6, pp. 633-662, (1993).
Gullikson, G. W., et al., Gastrointestinal Motility Responses to the S and R Enantiomers of Zacopride, a 5-HT4 Agonist and 5-HT3 Antagonist,Drug Development Research. vol. 26, pp. 405-417, (1992).
Eglen, R. M., et al., Central 5-HT4receptors,TiPS, vol. 16, pp. 391-398, (1995).
Bockaert, J., et al., 5-HT4Receptors Potential Therapeutic Implications in Neurology and Psychiatry,CNS Drugs, vol. 1, No. 1, pp. 6-15, (1994).
Romanelli, M. N., et al., Synthesis and Biological Activity of a Series of Aryl Tropanyl Esters and Amides Chemically Related to 1H-indole-3-carboxylic Acid endo 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl Ester,Arzneim.-Forsch./Drug Res., vol. 43 (II), No. 8, pp. 913-918, (1993).
Kaumann, A. J., et al. A 5-HT4-like receptor in human right atrium,Naunyn-Schmiedeberg's Arch Pharmacol., vol. 344, pp. 15-0-159, (1991).
Haleblian, J. K., Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications,Journal of Pharmaceutical Sciencesvol. 64, No. 8, pp. 1269-1288, 1975.
Areschka, A., et al., Recherches dans la serie des benzofurannes. LXI. Benzofurannyl-3 acetamidoximes a potentialities antihypertensives (*),Eur. J. Med. Chem.—Chimica Therapuetica, vol. 12, No. 1, pp. 87-91 (1977) (with English language abstract).
Liang, A. C., et al., Fast-dissolving intraoral drug delivery systems,Expert Opin. Ther. Patents, vol. 11, No. 6, pp. 981-986 (2001).
Verma, R. K., et al., Current Status of Drug Delivery Technologies and Future Directions,Pharmaceutical Technology On-Line, vol. 25, No. 2, pp. 1-14, (2001).
Finnin, B. C., et al., Transdermal Penetration Enhancers: Applications, Limitations, and Potential,Journal of Pharmaceutical Sciences, vol. 88, No. 1, pp. 955-958 (1999).
Yee, S., In vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth,Pharmceutical Resesarch, vol. 14, No. 6, pp. 763-766, (1997).
Tschaen, D. M. et al., Asymmetric Synthesis of MK-0499,J. Org. Chem., vol. 60, pp. 4324-4330, (1995).
Tapia, I., et al., 2,3-Dihydro-2-oxo-1-H-benzimidazole-1-carboxamides with Selective Affinity for the 5-HT4Receptor: Synthesis and Structure—Affinity and Structure—Activity Relationships of a New Series of Partial Agonist and Antagonist Derivatives,J. Med. Chem., vol. 42, pp. 2870-2880, (1999).
Slougui, N., et al., Reaction of Chloromethylcarbene with Ketene Alkyl Silyl Acetals; A New Synthesis of 2-Methyl-2-alkenoic Esters,Synthesis, pp. 58-60, (1982).
Gorrichon, L., et al., Strucure O-Metallee de Lithiocycloalcanecarboxylates De t-Butyle,Journal of Organometallic Chemistry, vol. 252, pp. 267-274, (1983).
Prugh, J. D., et al., A Simple Method of Protecting a Secondary Amine with tert Butyloxycarbonyl (BOC) in the Presence of a Primary Amine,Synthetic Communications, vol. 22, No. 16, pp. 2357-2360, (1992).
Nishida, H., et al., Synthesis and Evaluation of 1-Arylsulfony1-3-piperazinone Derivatives as a Factor Xa Inhibitor II. Subsituent Effect on Biolog
Ando Koji
Iguchi Satoru
Murase Noriaki
Murata Yoshinori
Numata Toyoharu
Pfizer Inc.
Shameem Golam M
Smolizza Christian M.
Zielinski Bryan
LandOfFree
Benzimidazolone carboxylic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazolone carboxylic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazolone carboxylic acid derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202552